pioglitazone has been researched along with Acute Confusional Senile Dementia in 57 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus." | 9.15 | Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. ( Hanyu, H; Hirao, K; Iwamoto, T; Kanetaka, H; Sakurai, H; Sato, T, 2011) |
| "To evaluate the safety of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in nondiabetic patients with Alzheimer disease (AD) and to explore treatment effect sizes on clinical outcomes." | 9.15 | A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. ( Fritsch, T; Geldmacher, DS; Landreth, G; McClendon, MJ, 2011) |
| "We used the F344 rat model of aging, and monitored behavioral, electrophysiological, and molecular variables to assess the effects of pioglitazone (PIO-Actos(R) a TZD) on several peripheral (blood and liver) and central (hippocampal) biomarkers of aging." | 7.76 | Effects of long-term pioglitazone treatment on peripheral and central markers of aging. ( Anderson, KL; Avdiushko, MG; Blalock, EM; Chen, KC; Cohen, DA; Gant, JC; Pancani, T; Phelps, JT; Popovic, J; Porter, NM; Searcy, JL; Thibault, O, 2010) |
| "Treatment with pioglitazone ameliorated Aβ42 deposition in the hippocampus by increasing IDE and PPARγ expression." | 5.46 | Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation. ( Cao, M; Chen, Z; Li, R; Wang, Z; Yang, S; Zhang, M, 2017) |
| "Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, is known to have anti-inflammatory and anti-oxidant effects on the brain, and its clinical potential in the treatment of cognitive impairment in diseases such as Alzheimer's disease (AD) and Parkinson disease (PD) is currently being explored." | 5.22 | Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature. ( Aldubayan, M; Alhowail, A; Alsaud, M; Alsikhan, R; Rabbani, SI, 2022) |
| "To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus." | 5.15 | Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. ( Hanyu, H; Hirao, K; Iwamoto, T; Kanetaka, H; Sakurai, H; Sato, T, 2011) |
| "To evaluate the safety of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in nondiabetic patients with Alzheimer disease (AD) and to explore treatment effect sizes on clinical outcomes." | 5.15 | A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. ( Fritsch, T; Geldmacher, DS; Landreth, G; McClendon, MJ, 2011) |
| "We used the F344 rat model of aging, and monitored behavioral, electrophysiological, and molecular variables to assess the effects of pioglitazone (PIO-Actos(R) a TZD) on several peripheral (blood and liver) and central (hippocampal) biomarkers of aging." | 3.76 | Effects of long-term pioglitazone treatment on peripheral and central markers of aging. ( Anderson, KL; Avdiushko, MG; Blalock, EM; Chen, KC; Cohen, DA; Gant, JC; Pancani, T; Phelps, JT; Popovic, J; Porter, NM; Searcy, JL; Thibault, O, 2010) |
| "The onset of mild cognitive impairment (MCI) is an essential outcome in Alzheimer's disease (AD) prevention trials and a compelling milestone for clinically meaningful change." | 3.11 | Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial. ( Alexander, R; Bennett, DA; Burns, DK; Chiang, C; Culp, M; Farlow, MR; Haneline, S; Maresca, S; O'Neil, J; Peskind, ER; Raskind, MA; Sano, M; Saunders, AM; Schneider, LS; Stern, Y; Walter, R; Welsh-Bohmer, KA, 2022) |
| " There were no other notable differences in adverse events between groups." | 3.01 | Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. ( Alexander, RC; Burke, JR; Burns, DK; Chiang, C; Culp, M; Evans, RM; Haneline, S; Harrigan, P; Lutz, MW; O'Neil, J; Plassman, BL; Ratti, E; Saunders, AM; Schneider, LS; Schwarz, AJ; Welsh-Bohmer, KA; Wu, J; Yaffe, K, 2021) |
| "Similar insulin resistance is found in type 2 diabetes and is currently treated with insulin sensitizers (IS)." | 2.61 | A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. ( Craig, A; Issberner, J; Parvez, F, 2019) |
| "Pioglitazone (AD4833) is an insulin sensitizer of the thiazolidinedione class of nuclear Peroxisome-Proliferator Activated Receptor γ (PPARγ) agonists." | 2.55 | Pioglitazone for the treatment of Alzheimer's disease. ( Galimberti, D; Scarpini, E, 2017) |
| "Rosiglitazone was not efficacious, even for apolipoprotein E (APOE) ε4 non-carriers (MD -0." | 2.52 | Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis. ( Jia, JP; Liu, J; Wang, LN, 2015) |
| "Pioglitazone is an insulin resistance inhibitor widely used as monotherapy or combined with metformin or insulin in treating type 2 diabetes mellitus (T2DM)." | 1.91 | Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin. ( Chen, CC; Chen, LC; Chien, WC; Chung, CH; Huang, KY; Lin, HA; Lin, HC; Tsai, MH; Wang, JY, 2023) |
| "Treatment with fenofibrate, pioglitazone and their combination resulted in a significant improvement in the behavioural and neurochemical changes induced by βA injection." | 1.56 | Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases. ( Assaf, N; El Sayed, NS; El-Shamarka, ME; Khadrawy, YA; Salem, NA, 2020) |
| "Pioglitazone (PGZ) is a member of the thiazolidinedione (TZDs) family of drugs and it is primarily used to treat type 2 diabetes." | 1.51 | Thiazolidinedione as an alternative to facilitate oral administration in geriatric patients with Alzheimer's disease. ( Calpena, AC; Espina, M; Espinoza, LC; García, ML; Gonzalez-Pizarro, R; Rodríguez-Lagunas, MJ; Silva-Abreu, M, 2019) |
| "Growing evidence suggest that Alzheimer's disease (AD), the most common cause of dementia among the elderly is a metabolic disorder associated with impaired brain insulin signaling." | 1.51 | Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design. ( De, A; Jojo, GM; Karri, VVSNR; Kuppusamy, G, 2019) |
| "Treatment with pioglitazone ameliorated Aβ42 deposition in the hippocampus by increasing IDE and PPARγ expression." | 1.46 | Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation. ( Cao, M; Chen, Z; Li, R; Wang, Z; Yang, S; Zhang, M, 2017) |
| "Pioglitazone treatment rescued a third of these proteins, mainly those associated with oxidative stress, promotion of cerebrovascular vasocontractile tone, and vascular compliance." | 1.46 | Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone. ( Badhwar, A; Brown, R; Hamel, E; Haqqani, AS; Stanimirovic, DB, 2017) |
| "To successfully treat Alzheimer's disease (AD), pathophysiological events in preclinical stages need to be identified." | 1.43 | Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer's disease. ( Dorostkar, MM; Herms, J; Ohli, J; Schüller, U; Shi, Y; Zou, C, 2016) |
| "Sporadic Alzheimer's disease (AD) is a multifactorial metabolic brain disorder characterized by progressive neurodegeneration." | 1.42 | Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. ( Blanchard, J; Gong, CX; Iqbal, K; Li, X; Li, Y; Liu, F; Yu, Y, 2015) |
| " When mice were dosed with racemic pioglitazone, the concentration of (+)-pioglitazone was 46." | 1.42 | Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease. ( Chang, KL; Ho, PC; Pee, HN; Yang, S, 2015) |
| " The current study was carried out to investigate the effects of chronic administration of pioglitazone, a PPAR-γ agonist, on cognitive impairment in an animal model of Alzheimer's disease induced by β-amyloid." | 1.40 | Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease. ( Kumar, A; Prakash, A, 2014) |
| "Animal models of Alzheimer's disease (AD) are invaluable in dissecting the pathogenic mechanisms and assessing the efficacy of potential new therapies." | 1.39 | Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathology. ( Hamel, E; Papadopoulos, P; Rochford, J; Rosa-Neto, P, 2013) |
| "Although modulating disease progression is an attractive target and will alleviate the burden of the most severe stages, this strategy will not reduce the prevalence of the disease itself." | 1.39 | Using genetics to enable studies on the prevention of Alzheimer's disease. ( Brannan, SK; Burke, JR; Burns, DK; Crenshaw, DG; Gottschalk, WK; Grossman, I; Lutz, MW; Roses, AD; Saunders, AM; Welsh-Bohmer, KA, 2013) |
| " The current study was carried out to investigate the effects of chronic administration of pioglitazone, a PPAR-γ agonist, on cognitive impairment in a mouse model of Alzheimer's disease induced by scopolamine." | 1.38 | Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease. ( Gupta, LK; Gupta, R, 2012) |
| "Alzheimer's disease is associated with a disruption of amyloid β (Aβ) homeostasis, resulting in the accumulation and subsequent deposition of Aβ peptides within the brain." | 1.38 | Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. ( Karlo, JC; Landreth, GE; Mandrekar-Colucci, S, 2012) |
| "Neuritic plaques in the brain of Alzheimer's disease patients are characterized by beta-amyloid deposits associated with a glia-mediated inflammatory response." | 1.33 | Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. ( Dewachter, I; Dumitrescu-Ozimek, L; Hanke, A; Heneka, MT; Klockgether, T; Kuiperi, C; Landreth, GE; O'Banion, K; Sastre, M; Van Leuven, F, 2005) |
| "Ibuprofen treatment resulted in 60% reduction of amyloid plaque load in the cortex of these animals." | 1.32 | Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. ( Babu-Khan, S; Biere, AL; Citron, M; Landreth, G; Liu, H; Vassar, R; Yan, Q; Zhang, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (10.53) | 29.6817 |
| 2010's | 40 (70.18) | 24.3611 |
| 2020's | 11 (19.30) | 2.80 |
| Authors | Studies |
|---|---|
| Gandini, A | 1 |
| Bartolini, M | 1 |
| Tedesco, D | 1 |
| Martinez-Gonzalez, L | 1 |
| Roca, C | 1 |
| Campillo, NE | 1 |
| Zaldivar-Diez, J | 1 |
| Perez, C | 1 |
| Zuccheri, G | 1 |
| Miti, A | 1 |
| Feoli, A | 1 |
| Castellano, S | 1 |
| Petralla, S | 1 |
| Monti, B | 1 |
| Rossi, M | 1 |
| Moda, F | 1 |
| Legname, G | 1 |
| Martinez, A | 1 |
| Bolognesi, ML | 1 |
| Biechele, G | 2 |
| Blume, T | 1 |
| Deussing, M | 1 |
| Zott, B | 1 |
| Shi, Y | 2 |
| Xiang, X | 1 |
| Franzmeier, N | 1 |
| Kleinberger, G | 1 |
| Peters, F | 1 |
| Ochs, K | 1 |
| Focke, C | 1 |
| Sacher, C | 1 |
| Wind, K | 1 |
| Schmidt, C | 1 |
| Lindner, S | 1 |
| Gildehaus, FJ | 1 |
| Eckenweber, F | 2 |
| Beyer, L | 1 |
| von Ungern-Sternberg, B | 1 |
| Bartenstein, P | 2 |
| Baumann, K | 1 |
| Dorostkar, MM | 2 |
| Rominger, A | 1 |
| Cumming, P | 1 |
| Willem, M | 1 |
| Adelsberger, H | 1 |
| Herms, J | 3 |
| Brendel, M | 2 |
| Alhowail, A | 1 |
| Alsikhan, R | 1 |
| Alsaud, M | 1 |
| Aldubayan, M | 1 |
| Rabbani, SI | 1 |
| Schneider, LS | 2 |
| Bennett, DA | 1 |
| Farlow, MR | 1 |
| Peskind, ER | 1 |
| Raskind, MA | 1 |
| Sano, M | 1 |
| Stern, Y | 1 |
| Haneline, S | 2 |
| Welsh-Bohmer, KA | 3 |
| O'Neil, J | 2 |
| Walter, R | 1 |
| Maresca, S | 1 |
| Culp, M | 2 |
| Alexander, R | 1 |
| Saunders, AM | 4 |
| Burns, DK | 4 |
| Chiang, C | 2 |
| Lin, HC | 1 |
| Chung, CH | 1 |
| Chen, LC | 1 |
| Wang, JY | 1 |
| Chen, CC | 1 |
| Huang, KY | 1 |
| Tsai, MH | 1 |
| Chien, WC | 1 |
| Lin, HA | 1 |
| Kunze, LH | 1 |
| Ruch, F | 1 |
| Wind-Mark, K | 1 |
| Dinkel, L | 1 |
| Feyen, P | 1 |
| Ziegler, S | 1 |
| Paeger, L | 1 |
| Tahirovic, S | 1 |
| Yang, J | 1 |
| Shi, X | 1 |
| Wang, Y | 1 |
| Ma, M | 1 |
| Liu, H | 2 |
| Wang, J | 1 |
| Xu, Z | 1 |
| Assaf, N | 1 |
| El-Shamarka, ME | 1 |
| Salem, NA | 1 |
| Khadrawy, YA | 1 |
| El Sayed, NS | 1 |
| Ahn, KC | 1 |
| Learman, CR | 1 |
| Baker, GB | 1 |
| Weaver, CL | 1 |
| Chung, PS | 1 |
| Kim, HG | 1 |
| Song, MS | 1 |
| Liu, Y | 1 |
| Hanson, KA | 1 |
| McCormack, G | 1 |
| Atkinson, RAK | 1 |
| Dittmann, J | 1 |
| Vickers, JC | 1 |
| Fernandez-Martos, CM | 1 |
| King, AE | 1 |
| Mohamed, HE | 2 |
| Asker, ME | 2 |
| Shaheen, MA | 2 |
| Eissa, RG | 2 |
| Younis, NN | 2 |
| Alexander, RC | 1 |
| Evans, RM | 1 |
| Harrigan, P | 1 |
| Plassman, BL | 1 |
| Burke, JR | 2 |
| Wu, J | 1 |
| Lutz, MW | 3 |
| Schwarz, AJ | 1 |
| Yaffe, K | 1 |
| Ratti, E | 1 |
| Yang, S | 3 |
| Chen, Z | 1 |
| Cao, M | 1 |
| Li, R | 1 |
| Wang, Z | 1 |
| Zhang, M | 1 |
| Silva-Abreu, M | 2 |
| Calpena, AC | 2 |
| Andrés-Benito, P | 1 |
| Aso, E | 1 |
| Romero, IA | 1 |
| Roig-Carles, D | 1 |
| Gromnicova, R | 1 |
| Espina, M | 2 |
| Ferrer, I | 1 |
| García, ML | 2 |
| Male, D | 1 |
| Gonzalez-Pizarro, R | 1 |
| Espinoza, LC | 1 |
| Rodríguez-Lagunas, MJ | 1 |
| Jojo, GM | 2 |
| Kuppusamy, G | 2 |
| De, A | 1 |
| Karri, VVSNR | 1 |
| Chang, KL | 2 |
| Wong, LR | 1 |
| Pee, HN | 2 |
| Ho, PC | 2 |
| Craig, A | 1 |
| Parvez, F | 1 |
| Issberner, J | 1 |
| Papadopoulos, P | 1 |
| Rosa-Neto, P | 2 |
| Rochford, J | 1 |
| Hamel, E | 3 |
| Prakash, A | 1 |
| Kumar, A | 1 |
| Roses, AD | 2 |
| Zhang, N | 1 |
| Hariri, AR | 1 |
| Asin, KE | 1 |
| Crenshaw, DG | 2 |
| Budur, K | 1 |
| Brannan, SK | 2 |
| Read, S | 1 |
| Wu, P | 1 |
| Biscow, M | 1 |
| Spinney, L | 1 |
| Yu, Y | 1 |
| Li, X | 1 |
| Blanchard, J | 1 |
| Li, Y | 1 |
| Iqbal, K | 1 |
| Liu, F | 1 |
| Gong, CX | 1 |
| Liu, J | 1 |
| Wang, LN | 1 |
| Jia, JP | 1 |
| Chen, J | 1 |
| Li, S | 1 |
| Sun, W | 1 |
| Li, J | 1 |
| Savage, JC | 1 |
| Jay, T | 1 |
| Goduni, E | 1 |
| Quigley, C | 1 |
| Mariani, MM | 1 |
| Malm, T | 1 |
| Ransohoff, RM | 1 |
| Lamb, BT | 1 |
| Landreth, GE | 4 |
| Cheng, H | 1 |
| Shang, Y | 1 |
| Jiang, L | 1 |
| Shi, TL | 1 |
| Wang, L | 1 |
| Skerrett, R | 1 |
| Pellegrino, MP | 1 |
| Casali, BT | 1 |
| Taraboanta, L | 1 |
| Zou, C | 1 |
| Ohli, J | 1 |
| Schüller, U | 1 |
| Toba, J | 1 |
| Nikkuni, M | 1 |
| Ishizeki, M | 1 |
| Yoshii, A | 1 |
| Watamura, N | 1 |
| Inoue, T | 1 |
| Ohshima, T | 1 |
| DiBattista, AM | 1 |
| Dumanis, SB | 1 |
| Newman, J | 1 |
| Rebeck, GW | 1 |
| Badhwar, A | 1 |
| Brown, R | 1 |
| Stanimirovic, DB | 1 |
| Haqqani, AS | 1 |
| Galimberti, D | 1 |
| Scarpini, E | 1 |
| Nicolakakis, N | 1 |
| Aboulkassim, T | 1 |
| Ongali, B | 1 |
| Lecrux, C | 1 |
| Fernandes, P | 1 |
| Tong, XK | 1 |
| Hanyu, H | 3 |
| Sato, T | 3 |
| Kiuchi, A | 1 |
| Sakurai, H | 3 |
| Iwamoto, T | 3 |
| Roberts, JC | 1 |
| Friel, SL | 1 |
| Roman, S | 1 |
| Perren, M | 1 |
| Harper, A | 1 |
| Davis, JB | 1 |
| Richardson, JC | 1 |
| Virley, D | 1 |
| Medhurst, AD | 1 |
| Hirao, K | 1 |
| Kanetaka, H | 1 |
| Blalock, EM | 2 |
| Phelps, JT | 2 |
| Pancani, T | 2 |
| Searcy, JL | 2 |
| Anderson, KL | 2 |
| Gant, JC | 1 |
| Popovic, J | 2 |
| Avdiushko, MG | 1 |
| Cohen, DA | 1 |
| Chen, KC | 2 |
| Porter, NM | 2 |
| Thibault, O | 2 |
| Baraka, A | 1 |
| ElGhotny, S | 1 |
| Geldmacher, DS | 1 |
| Fritsch, T | 1 |
| McClendon, MJ | 1 |
| Landreth, G | 2 |
| Sakurai, T | 1 |
| Miller, BW | 1 |
| Willett, KC | 1 |
| Desilets, AR | 1 |
| Xiang, GQ | 1 |
| Tang, SS | 1 |
| Jiang, LY | 1 |
| Hong, H | 1 |
| Li, Q | 1 |
| Wang, C | 1 |
| Wang, XY | 1 |
| Zhang, TT | 1 |
| Yin, L | 1 |
| Kadish, I | 1 |
| Beckett, TL | 1 |
| Murphy, MP | 1 |
| Landfield, PW | 1 |
| Gupta, R | 1 |
| Gupta, LK | 1 |
| Mandrekar-Colucci, S | 1 |
| Karlo, JC | 1 |
| Yamanaka, M | 1 |
| Ishikawa, T | 1 |
| Griep, A | 1 |
| Axt, D | 1 |
| Kummer, MP | 1 |
| Heneka, MT | 2 |
| Gottschalk, WK | 1 |
| Grossman, I | 1 |
| Masciopinto, F | 1 |
| Di Pietro, N | 1 |
| Corona, C | 1 |
| Bomba, M | 1 |
| Pipino, C | 1 |
| Curcio, M | 1 |
| Di Castelnuovo, A | 1 |
| Ciavardelli, D | 1 |
| Silvestri, E | 1 |
| Canzoniero, LM | 1 |
| Sekler, I | 1 |
| Pandolfi, A | 1 |
| Sensi, SL | 1 |
| Yan, Q | 1 |
| Zhang, J | 1 |
| Babu-Khan, S | 1 |
| Vassar, R | 1 |
| Biere, AL | 1 |
| Citron, M | 1 |
| Sastre, M | 1 |
| Dumitrescu-Ozimek, L | 1 |
| Hanke, A | 1 |
| Dewachter, I | 1 |
| Kuiperi, C | 1 |
| O'Banion, K | 1 |
| Klockgether, T | 1 |
| Van Leuven, F | 1 |
| Galea, E | 1 |
| Feinstein, DL | 1 |
| Lacombe, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Effica[NCT01931566] | Phase 3 | 3,494 participants (Actual) | Interventional | 2013-08-01 | Terminated (stopped due to Lack of efficacy of the drug; no safety concern) | ||
| Pioglitazone in Alzheimer Disease Progression[NCT00982202] | Phase 2 | 25 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Composite scores derived from the test battery. Domains of Episodic Memory [California Verbal Learning Test-2nd Edition (CVLT-II), Brief Visuospatial Memory Test-Revised (BVMT-R)]; Executive Function [Trail Making Test (TMT) (Part B), Wechsler Adult Intelligence Scale (WAIS)-III Digit Span Test-backwards span]; Language [Multilingual Naming Test (MiNT), Semantic Fluency (animals), Lexical/phonemic fluency (F, A, and S in English; D, S, and F in German)]; and Attention [WAIS-III Digit Span Test-forward span, TMT (Part A)] used for composite score. 12 measures were derived from 8 neuropsychological tests. CVLT-II test involved 2 primary measures (short, long delay recall); BVMT-R had 2 measures (copy and recall); Digit Span and Trail both had 2 measures (forward and backward span and Parts A and B). There was 1 total score for each test: CDT, MINT, semantic and lexical fluency. Total score ranged from -1.222 to 1.707 at baseline, a higher composite score indicated better cognition. (NCT01931566)
Timeframe: Baseline and Month 48
| Intervention | score on a scale (Mean) |
|---|---|
| High Risk Placebo | 0.1841 |
| High Risk Pioglitazone | 0.1687 |
The ADCS ADL-PI is a functional measure that was specifically designed for standardized administration over long duration clinical studies to prevent AD. The ADCS ADL-PI is a 20-item instrument that included 15 ADL questions, which were scored as 1 (with a lot of difficulty), 2 (with some difficulty), or 3 (as well as usually, with no difficulty), plus 5 vision, hearing, and mobility questions, which were scored from 0 (no) to 1 (yes). ADL Total ranged from 0 to 45, and lower scores indicated greater disability. (NCT01931566)
Timeframe: Baseline and Month 48
| Intervention | score on a scale (Mean) |
|---|---|
| High Risk Placebo | 0.1 |
| High Risk Pioglitazone | 0.3 |
The event definition for MCI-AD was the time in days from the randomization date to the date of the first of two consecutive scheduled visits at which a participant was assessed with a diagnosis of MCI due to AD confirmed by adjudication committee. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to the largest event time. (NCT01931566)
Timeframe: Baseline to the end of study (approximately up to 5 years)
| Intervention | days (Mean) |
|---|---|
| High Risk Placebo | 1238.67 |
| High Risk Pioglitazone | 1261.24 |
The event definition for MCI-AD was the time in days from the randomization date to the date of the first of two consecutive scheduled visits at which a participant was assessed with a diagnosis of MCI due to AD confirmed by adjudication committee. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to the largest event time. (NCT01931566)
Timeframe: Baseline to the end of study (approximately up to 5 years)
| Intervention | days (Mean) |
|---|---|
| Low Risk Placebo | 905.44 |
| High Risk Placebo | 1238.67 |
10 reviews available for pioglitazone and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature.
Topics: Alzheimer Disease; Antioxidants; Cognitive Dysfunction; Humans; Hypoglycemic Agents; Parkinson Disea | 2022 |
Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer's Disease via Neuroinflammation and Ferroptosis.
Topics: Alzheimer Disease; Ferroptosis; Humans; Neuroinflammatory Diseases; Neuroprotection; Pioglitazone; P | 2023 |
Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Astrocytes; Brain; Cerebrovascular Disorders; Diabetes Mel | 2019 |
Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chemistry, Pharmaceutical; Drug Repositioning; Humans; Hypoglycemic Agen | 2019 |
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; | 2019 |
New applications of disease genetics and pharmacogenetics to drug development.
Topics: Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Animals; Brain; Clinical Trials, Phase III a | 2014 |
Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cognitive Dysfunction; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Ran | 2015 |
The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.
Topics: Alzheimer Disease; Benzimidazoles; Benzoates; Humans; Pioglitazone; PPAR gamma; Rosiglitazone; Telmi | 2016 |
Pioglitazone for the treatment of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Cognition; Dementia; Disease Progression; Humans; Hypoglycemic Age | 2017 |
Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Piogli | 2011 |
6 trials available for pioglitazone and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial.
Topics: Alzheimer Disease; Cognitive Dysfunction; Humans; Pioglitazone; Reproducibility of Results; Research | 2022 |
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers, Pharmacological; Cognitive Dysfunction; Doub | 2021 |
Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Diabetes Mellitus; Female; Humans; | 2009 |
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Diabetes Mellitus, Type 2; Female; | 2011 |
The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cognition; Female; Humans; Male; Pioglitazone; PPAR gamma; Thiazolidinedion | 2010 |
A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Glucose; Double-Blind Method; Female; Humans; Male | 2011 |
41 other studies available for pioglitazone and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Central Nervous System Agents; Circular Dichroism; | 2018 |
Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Female; Immunity, | 2021 |
Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Piogl | 2023 |
Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Mice; Mice, Transgenic; M | 2023 |
Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cognitive D | 2020 |
Enhanced Anti-Amyloid Effect of Combined Leptin and Pioglitazone in APP/PS1 Transgenic Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Hippocampus; Humans; Hypo | 2020 |
Alleviation of fructose-induced Alzheimer's disease in rats by pioglitazone and decaffeinated green coffee bean extract.
Topics: Alzheimer Disease; Animals; Antioxidants; Coffee; Fructose; Pioglitazone; Plant Extracts; Rats | 2021 |
Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Diet; Glycogen Synthase Kinase 3 beta; Insulin Re | 2017 |
Modulation of brain insulin signaling in Alzheimer's disease: New insight on the protective role of green coffee bean extract.
Topics: Alzheimer Disease; Animals; Brain; Coffee; Hippocampus; Insulin; Insulin Resistance; Male; Neuroprot | 2020 |
PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Blood-Brain Barrier; Cells, Cultured; Di | 2018 |
Thiazolidinedione as an alternative to facilitate oral administration in geriatric patients with Alzheimer's disease.
Topics: Administration, Sublingual; Alzheimer Disease; Animals; Diabetes Mellitus, Type 2; Diffusion; Humans | 2019 |
Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Cell Line, Tumor | 2019 |
Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonist.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Catalase; Cerebellum; Cerebral Cortex; C | 2019 |
Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Blotting, Western; Cerebrov | 2013 |
Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain-Derived Neurotrophic Factor; Cognition Diso | 2014 |
Sustained 4-year cognitive and functional response in early Alzheimer's disease with pioglitazone.
Topics: Aged; Alzheimer Disease; Cognition; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Memory; Pi | 2014 |
Alzheimer's disease: The forgetting gene.
Topics: Age of Onset; Alleles; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoprotein E2; Apolipo | 2014 |
Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.
Topics: Alzheimer Disease; Animals; Body Weight; Brain; Disease Models, Animal; Exploratory Behavior; Female | 2015 |
Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; ATP Binding Casse | 2015 |
Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cells, Cultured; Cyclin-Dependent Kinase 5; Disea | 2015 |
Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Axl Receptor Tyrosine Kinase; Benzoates; Benzylamines; Bexarotene; c-Mer | 2015 |
Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apolipoproteins E; Behavior, Animal; Ben | 2015 |
Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Anti-Inflammatory Agents; Aspartic | 2016 |
PPARγ agonist pioglitazone improves cerebellar dysfunction at pre-Aβ deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebellar Diseases; Intercellular Signaling Pept | 2016 |
Identification and modification of amyloid-independent phenotypes of APOE4 mice.
Topics: Age Factors; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipopr | 2016 |
Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Biomarkers; Blood | 2017 |
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.
Topics: Acetylcholine; Acetylcysteine; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2008 |
Autoradiographical imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice.
Topics: Acetamides; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid | 2009 |
Effects of long-term pioglitazone treatment on peripheral and central markers of aging.
Topics: Aging; Alzheimer Disease; Animals; Biomarkers; Brain; Hippocampus; Hypoglycemic Agents; Inflammation | 2010 |
Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Brain; | 2010 |
Targets of the peroxisome proliferator-activated receptor γ agonist trials for the prevention of Alzheimer disease.
Topics: Alzheimer Disease; Drug Delivery Systems; Humans; Pioglitazone; PPAR gamma; Thiazolidinediones | 2011 |
PPARγ agonist pioglitazone improves scopolamine-induced memory impairment in mice.
Topics: Administration, Oral; Alzheimer Disease; Animals; Avoidance Learning; Cerebral Cortex; Disease Model | 2012 |
Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biomarkers; Brain Chemistry; Disease Models, Animal; Drug Administration | 2012 |
Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Male; Maze Learning; | 2012 |
Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; Astrocytes; Brain; Cells, Cult | 2012 |
PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Brain; Cognition; Dise | 2012 |
Using genetics to enable studies on the prevention of Alzheimer's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Cognition; Disease Progression; | 2013 |
Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Female; Glucose; Humans; Male; Mice; | 2012 |
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory | 2003 |
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Amyloidosis; Animals | 2005 |
Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Brain; Carbon Radioisotopes; Deoxyglucose; Disease | 2006 |